Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANVS 
Annovis Bio Inc (ANVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: ANVS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.75
1 Year Target Price $13.75
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -89.65% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.33M USD | Price to earnings Ratio - | 1Y Target Price 13.75 |
Price to earnings Ratio - | 1Y Target Price 13.75 | ||
Volume (30-day avg) 4 | Beta 1.64 | 52 Weeks Range 1.11 - 10.54 | Updated Date 09/14/2025 |
52 Weeks Range 1.11 - 10.54 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -111.68% | Return on Equity (TTM) -365.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 31195566 | Price to Sales(TTM) - |
Enterprise Value 31195566 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.57 | Shares Outstanding 19486200 | Shares Floating 15590933 |
Shares Outstanding 19486200 | Shares Floating 15590933 | ||
Percent Insiders 14.86 | Percent Institutions 14.59 |
Upturn AI SWOT
Annovis Bio Inc
Company Overview
History and Background
Annovis Bio, Inc. (AVIS) is a clinical-stage drug platform company addressing neurodegenerative diseases. Founded in 2009, it focuses on developing therapies for Alzheimer's and Parkinson's diseases.
Core Business Areas
- Drug Development: Development of therapeutics targeting neurodegenerative diseases. The primary focus is on its lead drug candidate, buntanetap, which aims to inhibit the synthesis of neurotoxic proteins.
Leadership and Structure
Dr. Maria L. Maccecchini is the President and CEO. The company has a board of directors that oversees strategic direction.
Top Products and Market Share
Key Offerings
- Buntanetap: An oral drug candidate designed to inhibit the synthesis of neurotoxic proteins, potentially treating Alzheimer's and Parkinson's diseases. Since the drug is still in clinical trials, there is no revenue or market share. Competitors in Alzheimer's include Biogen (BIIB), Eli Lilly (LLY), and Roche (ROG).
Market Dynamics
Industry Overview
The neurodegenerative disease market is substantial and growing due to an aging population. There is a high unmet need for effective treatments for Alzheimer's and Parkinson's diseases.
Positioning
Annovis Bio aims to address the root causes of neurodegeneration with a novel approach targeting multiple toxic proteins. It is a small player in a field dominated by large pharmaceutical companies.
Total Addressable Market (TAM)
The global market for Alzheimer's disease therapeutics is projected to reach hundreds of billions of USD annually. Annovis Bio is positioned to capture a portion of this market if buntanetap proves effective.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting multiple toxic proteins
- Oral drug administration
- Potential for disease modification
Weaknesses
- Limited financial resources
- Small company size
- Reliance on a single drug candidate
- No product currently on the market
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Government funding and grants
- Expansion to other neurodegenerative diseases
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- ROG
- SNY
Competitive Landscape
Annovis Bio competes with larger, more established pharmaceutical companies with significantly greater resources. Its competitive advantage lies in its novel therapeutic approach. The Market Shares stated above are market shares of Alzheimer's drugs.
Growth Trajectory and Initiatives
Historical Growth: Annovis Bio's growth is tied to the progress of its clinical trials and the capital raised to support them.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and potential partnerships.
Recent Initiatives: Initiatives focus on advancing buntanetap through clinical trials and exploring potential applications in other neurodegenerative diseases.
Summary
Annovis Bio is a high-risk, high-reward clinical-stage company with a novel approach to treating neurodegenerative diseases. Its success depends on the positive results of its clinical trials, and raising adequate funding. The major risks include clinical trial failures and competition from larger pharmaceutical companies with deeper pockets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Annovis Bio Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is an estimate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Annovis Bio Inc
Exchange NYSE | Headquaters Malvern, PA, United States | ||
IPO Launch date 2010-02-12 | Founder, CEO, President, Executive Director & Acting CFO Dr. Maria L. Maccecchini Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.annovisbio.com |
Full time employees 8 | Website https://www.annovisbio.com | ||
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.